European Medicines Agency Accepts MAA for Gout Drug
the Clinical Pain Advisor take:
The European Medicines Agency has accepted the Marketing Authorization Application (MAA) for lesinurad 200 mg tablets.
According to a press release from AstraZeneca, lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.
The MAA filing was based on data from three clinical trisl - the CLEAR1, CLEAR2 and CRYSTAL Phase 3 studies. CLEAR1 and CLEAR2 were 12-month, randomized placebo-controlled studies that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with allopurinol versus allopurinol alone, in symptomatic gout patients not achieving target serum uric acid (sUA) levels on their current allopurinol therapy.
CRYSTAL was a year-long randomized, placebo-controlled study that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with febuxostat compared to febuxostat alone in gout patients with tophi.
The combined therapies of lesinurad and an XO inhibitor provides a dual mechanism approach targeting both excretion and production of uric acid, according to the study results, which were published by Ardea Biosciences, a member of the AstraZeneca Group.
Gout is a painful form of inflammatory arthritis.
Clinical Pain Advisor Articles
- Replacing Sleep, Sedentary Behavior With Physical Activity Beneficial in Knee Osteoarthritis
- The Role of Psychological Factors in Phantom Limb Pain Reviewed
- FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis
- Ozone vs Corticosteroids May Provide Longer-Lasting Effects for Plantar Fasciitis
- Rates of Concurrent Opioid, Sedative-Hypnotic Prescription Fills in Veterans
- Ketamine: Mechanisms of Action, Uses in Pain Medicine, and Side Effects
- Cannabis May Be Effective for Migraine Treatment
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Integrating Psychological Interventions Into Chronic Pain Management
- Chronic Neck Pain: Generators, Clinical Examination, MRI Findings, and Differential Diagnosis
- Pregabalin May Not Improve Analgesia During Medical Abortion
- Investigational Treatment Shows Promise in Chronic Low Back Pain
- Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Pain Severity May Partly Mediate the Association Between Depression and Physical Performance in Knee OA